Novo Nordisk’s $4.7 Billion Bet on Akero Therapeutics: A Game Changer for MASH Treatment?
October 9, 2025
In a strategic move to bolster its offerings in the field of
- April 1, 2026
FDA, EMA, and regulatory affairs
In a strategic move to bolster its offerings in the field of
AstraZeneca’s recent commitment of billions of dollars to establish a cutting-edge active
In a landscape where innovation is met with both opportunity and challenges,
On October 8, 2025, Vinay Prasad, the director of the FDA’s Center
In a significant move for Eli Lilly, Peter Marks has been appointed
The anticipation surrounding the Centers for Medicare and Medicaid Services (CMS) announcement
In recent news from the biopharma sector, AstraZeneca has made significant strides
In a significant advancement for oncology, AstraZeneca and Daiichi Sankyo recently reported
The Centers of Excellence in Regulatory Science and Innovation (CERSI) program has
The biopharma industry is on the cusp of a significant breakthrough with
In the ever-evolving landscape of the biopharmaceutical industry, staying informed about recent
Artificial intelligence (AI) is heralded as a transformative force in the healthcare
